In response to the COVID-19 public health emergency, the Centers for Medicare and Medicaid Services (CMS) is implementing 12 new procedure codes to describe the introduction or infusion of therapeutics into the International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), effective Aug. 1, 2020.
|
Procedure Code |
Description |
|
XW013F5 |
Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 |
|
XW033E5 |
Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
|
XW033F5 |
Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
|
XW033G5 |
Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
|
XW033H5 |
Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
|
XW043E5 |
Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5 |
|
XW043F5 |
Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5 |
|
XW043G5 |
Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5 |
|
XW043H5 |
Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5 |
|
XW0DXF5 |
Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5 |
|
XW13325 |
Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
|
XW14325 |
Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5 |
These codes are available in NCTracks and providers may bill the codes effective with dates of service on or after Aug. 1, 2020.
Contact
NCTracks Call Center: 800-688-6696